Windlas Biotech · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Management repeatedly deflected questions on injectable utilization levels and sequential revenue progression, citing competitive sensitivity. Last disclosed injectable revenue was 'not encouraging' in Q4 FY25. Quarter-on-quarter improvement was claimed but not quantified.
Trade generics showed 25% YoY growth but 'lower' sequential growth vs Q4 FY25. Analyst questioned annual run rate target (₹200-225 crore); management attributed variation to tender timing and seasonal effects, advising annual rather than quarterly view.
Analyst asked about wallet share improvement in CDMO business with Schedule M implementation driving migration from unorganized players. Management acknowledged inability to track wallet share due to lack of published data and customer confidentiality, only monitoring client concentration metrics.
Analyst correctly noted that current depreciation run rate excludes Plant 6 impact. When Plant 6 is capitalized (expected late FY26), additional depreciation will begin, creating headwind to margins. Management confirmed 'extra depreciation starts kicking in' upon capitalization.
